Guidelines for the management of chronic hepatitis C in patients infected after substance use

Acta Gastro-Enterologica Belgica

Volumn 68, Issue 1, 2005, Pages 38-45

  Robaeys, G ^a   Buntinx, F ^b   Bottieau, E ^c   Bourgeois, S ^d   Brenard, R ^e   Colle, I ^f   De Bie, J ^a   Mathei C ^b,g   Mulkay, J P ^h   Van Damme, P ⁱ   Van Ranst, M ^j   Verrando, R ^k   Michielsen, P ^l  

^a DEPARTMENT OF CARDIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^d ZNA Campus Stuivenberg ^*  (Belgium)

^e Hopital St Joseph   (Belgium)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

^g Free Clinic   (Belgium)

^h SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

ⁱ UNIVERSITY OF ANTWERP   (Belgium)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^k Medisch Sociaal Opvang Centrum   (Belgium)

^l ANTWERP UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

Chronic; Depression; Drug therapy; Hepatitis A; Hepatitis B; Hepatitis C; Interferons; Liver transplantation; Ribavirin; Substance abuse; Vaccination

Indexed keywords

ANTIVIRUS AGENT; METHADONE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

CONFERENCE PAPER; EVIDENCE BASED MEDICINE; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; LIVER BIOPSY; MEDICAL SOCIETY; PRACTICE GUIDELINE; REINFECTION; SUBSTANCE ABUSE; SYSTEMATIC REVIEW;

ANTIDOTES; ANTIVIRAL AGENTS; BEHAVIOR THERAPY; BELGIUM; COMBINED MODALITY THERAPY; COMORBIDITY; EVIDENCE-BASED MEDICINE; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; MALE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 20144388974     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (67)

1. STRADER D.B., WRIGHT T., THOMAS D.L., SEEFF L.B. Diagnosis, management, and treatment of hepatitis C. Hepatology, 2004, 39: 1147-1171.
2. NELSON M.R., MATTHEWS G., BROOK M.G., MAIN J. BHIVA guidelines: coinfection with HIV and chronic hepatitis C virus. HIV Med., 2003, 4 Suppl 1: 52-62.
3. ALTER M.J., KRUSZON-MORAN D., NAINAN O.V., MC QUILLAN G.M., GAO F., MOYER L.A., KASLOW R.A., MARGOLIS H.S. The prevalence of hepatitis C virus infection in the United States, 1988 through, 1994. N. Engl. J. Med., 1999, 341: 556-562.
4. ALTER MJ. Prevention of spread of hepatitis C. Hepatology, 2002, 36: S93-98.
5. MATHEI C., BUNTINX F., VAN DAMME P. Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: a systematic review. J. Viral Hepat., 2002, 9: 157-173.
6. MATHEI C., ROBAEYS G., VAN RANST M., VAN DAMME P., BUNTINX F. The epidemiology of hepatitis C among drug users in Belgium. Acta Gastroenterol. Belg., 2005 (in press).
7. JOSE M., CURTU S., GAJARDO R., JORQUERA J.I. The effect of storage at different temperatures on the stability of Hepatitis C virus RNA in plasma samples. Biologicals, 2003, 31: 1-8.
8. DE MOREAU DE GERBEHEAYE A.I., BODEUS M., ROBERT A., HORSMANS Y., GOUBAU P. Stable hepatitis C virus RNA detection by RT-PCR during four days storage. BMC Infect. Dis., 2002, 2: 22.
9. FONTANA R.J., LOK A.S. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology, 2002, 36 (Suppl. 1): S57-64.
10. FOSTER G.R., GOLDIN R.D. Management of chronic viral hepatitis. 2002. Taylor and Francis Group, 11 New Fetter Lane, London EC4P 4EE.
11. PAWLOTSKY J.M. Use and interpretation of virological tests for hepatitis C. Hepatology, 2002, 36 (Suppl. 1): S65-73.
12. PONTISSO P., BELLATI G., BRUNETTO M., CHEMELLO L, COLLOREDO G., DI STEFANO R., NICOLETTI M., RUMI M.G., RUVOLETTO M.G., SOFFREDINI R., VALENZA L.M., COLUCCI G. Hepatitis C virus RNA profiles in chronically infected individuals: do they relate to disease activity? Hepatology, 1999, 29: 585-9.
13. YANO M., KUMADA H., KAGE M., IKEDA K., SHIMAMATSU K., INOUE O., HASHIMOTO E., LEFKOWITCH S.U., LUDWIG J., OKUDA K. The long-term pathological evolution of chronic hepatitis C. Hepatology, 1996, 23: 1334-40.
14. FONTAINE H., NALPAS B., POULET B., CARNOT F., ZYLBERBERG H., BRECHOT C., POL S. Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. Hum. Pathol., 2001, 32: 904-909.
15. MARCELLIN P., ASSELAH T., BOYER N. Fibrosis and disease progressionin hepatitis C. Hepatology, 2002, 36 (Suppl.1): S47-56.
16. MICHIELSEN P., BOTTIEAU E. Treatment of chronic hepatitis C in the setting of HIV co-infection. Acta Gastroenterologica Belgica, 2005 (in press).
17. GEBO K.A., HERLONG H.F., TORBENSON M.S., JENCKES M.W., CHANDER G., GHANEM K.G., EL-KAMARY S.S., SULKOWSKI M., BASS E.B. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology, 2002, 36 (Suppl.1): S161-172.
18. GEBO K.A., CHANDER G., JENCKES M.W., GHANEM K.G., HERLONG H.F., TORBENSON M.S., EL-KAMARY S.S., BASS E.B. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology, 2002, 36 (Suppl.1): S 84-92.
19. DE FRANCHIS R. Updating Consensus in Portal Hypertension: Report of the Baveno III. Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J. Hepatol., 2000, 33: 846-852.
20. BRUIX J., SHERMAN M., LLOVET J.M., BEAUGRAND M., LENCIONI R., BURROUGHS A. K., CHRISTENSEN E., PAGLIARO L., COLOMBO M., RODES J., for the EASL Panel of Experts on HCC. Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J. Hepatol., 2001, 35: 421-430.
21. THOMAS D.L. Hepatitis C and human immunodeficiency virus infection. Hepatology, 2002, 36 (Suppl. 1): S201-209.
22. KANE A., LLOYD J., ZAFFRAN M., SIMONSEN L., KANE M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull. World Health Organ., 1999, 77: 801-807.
23. VAN VLIERBERGHE H., BORBATH I., DELWAIDE J., HENRION J., MICHIELSEN P., VERSLYPE C. BASL guidelines for the surveillance, diagnosis and treatment of hepatocellular carcinoma. Acta Gastroenterol. Belg., 2004, 67: 14-25.
24. SYLVESTRE D. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend., 2002, 67: 103-107.
25. BACKMUND M., MEYER K., VON ZIELONK A M., EICHENLAUB D. Treatment of hepatitis C infection in injection drug users. Hepatology, 2001, 34: 188-193.
26. VAN THIEL D.H., ANANTHARAJU A., CREECH S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am. J. Gastroentol., 2003, 98: 2281-2288.
27. JOWETT S.L., AGARWAL K., SMITH B.C., CRAIG W., HEWETT M., BASSENDINE D.R., GILVARRY E., BURT A.D., BASSENDINE M.F. Managing chronic hepatitis C acquired through intravenous drug use. QJM, 2001, 94: 153-158.
28. BOURLIERE M., HALFON P., PORTAL I. Treatment of chronic hepatitis C in special groups. Gastroenterol. Clin. Biol., 2002, 26: B 238-247.
29. ROBAEYS G., VAN VLIERBERGHE H., MATHEI C., VAN RANST M., BRUCKERS L., BUNTINX F. Compliance and effect of treatment for chronic hepatitis C in intravenous drug users. J. Hepatol., 2003, 38 (Suppl. 2): 165.
30. SCHAEFER M., SCHMIDT F., FOLWACZNY C., LORENZ R., MARTIN G., SCHINDLBECK N., HELDWEIN W., SOYKA M., GRUNZE H., KOENIG A., LOESCHKE K. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003, 37: 443-451.
31. MAUSS S., BERGER F., GOELZ J., JACOB B., SCHMUTZ G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology, 2004, 40: 120-124.
32. COURNOT M., GLIBERT A., CASTEL F., DRUART F., IMANI K., LAUWERS-CANCES V., MORIN T. Management of hepatitis C in active drugs users: experience of an addiction care hepatology unit. Gastroenterol. Clin. Biol., 2004, 28: 533-539.
33. SCHAEFER M., HEINZ A., BACKMUND M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction, 2004, 99: 1167-1175.
34. KRESINA T.F., SEEFF L.B., FRANCIS H. Hepatitis C infection and injection drug use: the role of hepatologist in evolving treatment efforts. Hepatology, 2004, 40: 516-519.
35. ROBAEYS G., BUNTINX F. Treatment of hepatitis C viral infections in substance abusers in, 2005. Acta Gastroenterol. Belg., 2005 (in press).
36. EDLIN B.R., SEAL K.H., LORVICK J., KRAL A.H., CICCARONE D. H., MOORE L.D., LO B. Is It Justifiable to Withhold Treatment for Hepatitis C from Illicit-Drug Users? N. Engl. J. Med., 2001, 345: 211-214.
37. EDLIN B.R. Prevention and treatment of hepatitis C in injection drug users. Hepatology, 2002, 36: S210-S219.
38. VERRANDO R., ROBAEYS G., MATHEI C., BUNTINX F. Methadone and buprenorphine maintenance therapies for patients with hepatitis C virus infected after intravenous drug use. Acta Gastroenterol. Belg., 2005 (in press).
39. DE BIE J., ROBAEYS, G., BUNTINX F. Hepatitis C, interferon alpha and psychiatric co-morbidity in intravenous drug users (IVDU): Guidelines for clinical practice. Acta Gastroenterol. Belg., 2005 (in press).
40. WONG J.B., KOFF R.S. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effective analysis. Ann. Intern. Med., 2000, 133: 665-675.
41. CHANDER G., SULKOWSKI M.S., JENCKES M.W., TORBENSON M.S., HERLONG H.F., BASS E.B., GEBO K.A. Treatment of chronic hepatitis C: a systematic review. Hepatology. 2002, 36 (Suppl. 1): S135-144.
42. MICHIELSEN P., BRENARD R., BOURGEOIS N., DE GALOCSY CH., DELWAIDE J., HENRION J., HORSMANS Y., NEVENS F., REYNAERTS H., ROBAEYS G., SPRENGERS D., VAN VLIERBERGHE H. Hepatitis C: screening, treatment and prevention practical guidelines. Acta Gastroenterol. Belg., 2003, 66: 15-19.
43. GERLACH J.T., DIEPOLDER H.M., ZACHOVAL R., GRUENER N.H., JUNG M.C., ULSENHEIMER A., SCHRAUT W.W., SCHIRREN C.A., WAECHTLER M., BACKMUND M., PAPE G.R. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology, 2003, 125: 80-88.
44. DELWAIDE J., BOURGEOIS N., GERARD C., DE MAEGHT S., MOKADDEM F., WAIN E., BASTENS B., FEVERY J., GEHENOT M., LE MOINE O., MARTINET J.P., ROBAEYS G., SERVAIS B., VAN GOSSUM M., VAN VLIERBERGHE H. Treatment of acute hepatitis C with interferon alpha-2b: early initiation of treatment is the most effective predictive factor of sustained viral response. Aliment. Pharmacol. Ther., 2004, 20: 15-22.
45. JAECKEL E., CORNBERG M., WEDEMEYER H., SANTANTONIO T., MAYER J., ZANKEL M., PASTORE G., DIETRICH M., TRAUTWEIN C., MANNS M.P. Treatment of acute hepatitis C with interferon alfa-2b. N. Engl. J. Med., 2001: 1452-1456.
46. DAVIS G.L., WONG J.B., MC HUTCHISON J.G., MANNS M.P., HARVEY J., ALBRECHT J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology, 2003, 38: 645-52.
47. DI MARTINI A, WEINRIEB R. Hepatitis C in methadone maintenance patients: prevalence and public policy implications. Am. J. Transplant., 2003, 3: 1183-1184.
48. KANCHANA T.P., KAUL V., MANZARBEITIA C., REICH D.J., HAILS K.C., MUNOZ S.J., ROTHSTEIN K.D. Liver transplantation for patients on methadone maintenance. Liver Transpl., 2002, 8: 778-782.
49. WEINRIEB R.M., BARNETT R., LYNCH K.G., DE PIANO M., ATANDA A., OLTHOFF K.M. A matched comparison study of medical and psychiatric complications and anesthesia and analgesia requirements in methadone-maintained liver transplant recipients. Liver Transpl., 2004, 10: 97-106.
50. DI MARTINI A, WEINRIEB R, FIREMAN M. Liver transplantation in patients with alcohol and other substance use disorders. Psych. Clin. N. Amer., 2002, 25: 195-208.
51. KOCH M., BANYS P. Liver transplantation and opioid dependence. JAMA, 2001, 28: 1056-1058.
52. DIEPERINK E., HO S.B., THURAS P., WILLENBRING M.L. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics, 2003, 44: 104-112.
53. WICHERS M.C., KOEK G.H., ROBAEYS G., PRAAMSTRA A.J., MAES M. Early increase in vegetative symptoms predicts IFN-alpha-induced depression. Accepted: Psychological Medicine.
54. WICHERS M.C., KOEK G.H., ROBAEYS G., PRAAMSTRA A.J., MAES M. Involvement of indoleamine 2,3-dioxygenase (IDO) in IFN-alpha-induced depressive symptoms through its modulation of the kynurenine pathway. Accepted: Molecular Psychiatry.
55. HAUSER P., SOLER R., REED S., KANE R., GULATI M., KHOSLA J., KLING M.A., VALENTINE A.D., MEYERS C.A. Prophylactic treatment of depression induced by interferon-alpha. Psychosomatics, 2000, 41: 439-441.
56. MEHTA S.H., COX A., HOOVER D.R., WANG X.H., MAO Q., RAY S., STRATHDEE S.A., VLAHOV D., THOMAS D.L. Protection against persistence of hepatitis C. Lancet, 2002, 359: 1478-1483.
57. DALGARD K., BJORO K., HELLUM K., MYRVANG B., SKAUG K., GUTIGARD B., BELL H., and the Construct Group. Treatment of chronic hepatitis C in injecting drug users: 5 Years' Follow-Up. European Addiction Research, 2002, 8: 45-49.
58. QUAGLIO G., TALAMANI G., LUGOBONI F., LECHI A., VENTURINI L., JARLAIS D.C., MEZZELANI P. Compliance with hepatitis B vaccination in 1175 heroin users and risk factors associated with lack of vaccine response. Addiction, 2002, 97: 985-992.
59. LUM P.J., OCHOA K.C., HAHN J.A., SHAFER K.P., EVANS J.L., MOSS A.R. Hepatitis B virus immunization among young injection drug users in San Francisco, CA: The UFO study. Am. J. Public Health, 2003, 93: 919-923.
60. LAMAGNI T.L., HOPE V.D., DAVISON K.L., PARRY J.V., GILL O.N. Failure to vaccinate current injecting drug users against hepatitis B in England and Wales. Commun Dis. Public Health, 2001, 4: 71-72.
61. MC GREGOR J., MARKS, P.J., HAYWARD A., BELL Y., SLACK R.C. Factors influencing hepatitis B vaccine uptake in injecting drug users. J. Public Health Med., 2003, 25: 165-70.
62. SORIANO V., MIRO J.M., GARCIA -SAMANIEGO J., TORRE -CISNEROS J., NUNEZ M., DEL ROMERO J., MARTIN -CARBONERO L., CASTILLA J., IRIBARREN J.A., QUEREDA C., SANTIN M., GONZALEZ J., ARRIBAS J.R., SANTOS I., HERNANDEZ -QUERO J., ORTEGA E., ASENSI V., DEL POZO M.A., BERENGUER J., TURAL C., CLOTET B., LEAL M., MALLOLAS J., SANCHEZ-TAPIAS J.M., MORENO S., GATELL J.M., TELLEZ M.J., RUBIO R. LEDESMA E., DOMINGO P., BARREIRO P., PEDREIRA J., ROMERO M., GONZALEZ-LAHOZ J., LISSEN E. Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. J. Viral Hepat., 2004, 11: 2-17.
63. SORIANO V., PEREZ-OLMEDA M., RIOS P., NUNEZ M., GARCIA-SAMANIEGO J., LAHOZ-GONZALEZ J. Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients. AIDS Res. Hum. Retrov., 2004, 20: 351-353.
64. MAUSS S., VALENTI W.A., DEPAMPHILIS J.B., DUFF F.B., CUPELLI L.B., PASSE S.B., SOLSKY J.B., TORRIANI F.J.C., DIETERICH D.D., LARREY D.E. Risk factors for hepatic decompensation in patients with HIV/HCV co infection and liver cirrhosis during interferon-based therapy. AIDS, 2004, 18: 21-25.
65. POL S. Traitement de l'hépatite chronique C chez les malades ayant une co-infection VIH: Efficacité et tolérance. Gastroenterol. Clin. Biol., 2002, 26: B264-B273.
66. CARRAT F., BANI-SADR F., POL S., ROSENTHAL E., LUNEL-FABIANI F., BENZEKRI A., MORAND P., GOUJARD C., PIALOUX G., PIROTH L., SALMON-CERON D., DEGOTT C., CACOUB P., PERRONNE C., ANRS HCO2 RIBAVIC STUDY TEAM. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA, 2004, 292: 2839-2848.
67. TORRIANI F.J., RODIGUEZ-TORRES M., ROCKSTROH J.K., LISSEN E., GONZALEZ-GARCÍA J., LAZZARIN A., CAROSI G., SASADEUSZ J., KATLAMA C., MONTANER J., SETTE H. JR., PASSE S., DE PAMPHILIS J., DUFF F., SCHRENCK U.M., DIETERICH D.T., The APRICOT Study Group. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med., 2004, 351: 438-450.